uniQure N.V. (QURE) vs Stoke Therapeutics, Inc. (STOK)
A side-by-side comparison of uniQure N.V. and Stoke Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
QURE
uniQure N.V.
$23.06HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
STOK
Stoke Therapeutics, Inc.
$24.37HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — QURE vs STOK
growth of $100 · dividends reinvested · last 7yQURE -68.6% (-15.2%/yr)STOK -1.0% (-0.1%/yr)STOK compounded faster over this window
QURE STOK
QURE vs STOK: by the numbers
- •QURE is the larger company ($1.60B vs $1.57B market cap).
- •Both run net losses; STOK's is the smaller (-753.60% vs -1350.73% net margin).
Metrics side by side
Valuation
| Metric | QURE | STOK |
|---|---|---|
| P/S ratio | 85.67 | 57.00 |
| P/B ratio | 4.94 | 4.55 |
Profitability
| Metric | QURE | STOK |
|---|---|---|
| Gross margin | 89.53% | 100.00% |
| Operating margin | -1166.77% | -11.16% |
| Net margin | -1350.73% | -753.60% |
| ROE | -77.83% | -60.17% |
| ROIC | -22.55% | -63.12% |
Growth (annualized)
| Metric | QURE | STOK |
|---|---|---|
| Revenue CAGR (5Y) | -48.20% | N/A |
| Total return CAGR (5Y) | -6.16% | -0.24% |
Frequently asked
- How have QURE and STOK total returns compared?
- Over the past 5 years, QURE delivered -6.16% and STOK delivered -0.24% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.